DrugPatentWatch Database Preview

Ge Healthcare Company Profile

« Back to Dashboard

What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?

GE HEALTHCARE has fifty-four approved drugs.

There are seven US patents protecting GE HEALTHCARE drugs.

Summary for Ge Healthcare

US Patents:	7
Tradenames:	62
Ingredients:	42
NDAs:	54
Drug Master File Entries:	5
Patent Litigation for Ge Healthcare:	See patent lawsuits for Ge Healthcare

Drugs and US Patents for Ge Healthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	TECHNETIUM TC 99M GENERATOR	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS, ORAL	017693-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	TELEPAQUE	iopanoic acid	TABLET;ORAL	008032-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	GALLIUM CITRATE GA 67	gallium citrate ga-67	INJECTABLE;INJECTION	017700-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	AMIPAQUE	metrizamide	INJECTABLE;INJECTION	017982-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Ge Healthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	OMNIPAQUE 140	iohexol	INJECTABLE;INJECTION	018956-005	Nov 30, 1988	4,021,481
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	4,250,113
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994	4,250,113
Ge Healthcare	OMNISCAN	gadodiamide	INJECTABLE;INJECTION	020123-001	Jan 8, 1993	5,362,475

Non-Orange Book US Patents for Ge Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,875,420	Method of ultrasound imaging
7,854,920	Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
9,808,541	Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
5,393,524	Methods for selecting and using gases as ultrasound contrast media

International Patents for Ge Healthcare Drugs

Country	Document Number	Estimated Expiration
Slovenia	1611115
Japan	2012102106
Germany	605477
China	1073104

Supplementary Protection Certificates for Ge Healthcare Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C/GB97/078	United Kingdom		PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
C0005	Belgium		PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
595	Luxembourg		PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Ge Healthcare
• Ge Hlthcare Inc